Walmart (WMT) Stock Plunges 9% as Analysts Slash Targets Following Weak Q2 Sales Growth

Key Takeaways Walmart shares plummeted 9% to their lowest point in 2026 following Q2 earnings release Comparable sales in the US increased only 2.6%, significantly missing the projected 3.7% and marking the weakest performance in six years Transaction value growth slowed to just 1.1%, a sharp decline from the prior year’s 3.1% rate Goldman Sachs revised its price target downward from $141 to $130 while retaining its Buy recommendation BofA Securities reduced its price objective from $144 to $126, also maintaining a Buy stance Shares of Walmart plunged 9.2% on Thursday, reaching their lowest level in 2026, following the retail giant’s second-quarter earnings report that revealed troubling signs about American consumer health. The decline has pushed the stock more than 20% below its recent high. Walmart Inc., WMT While the retailer exceeded profit projections with adjusted earnings of $0.81 per share versus the anticipated $0.74, and revenues of $187.9 billion surpassed estimates of $186.75 billion, the market response was decidedly negative. The company even upgraded its annual outlook, yet investors weren’t convinced. The critical metric that disappointed was comparable store sales. When fuel is excluded, these sales climbed merely 2.6%, substantially below Wall Street’s 3.7% projection. This represents the weakest comparable sales expansion Walmart has delivered since the pandemic era. Removing the negative impact from its health and wellness division still left comparable sales at 3.4%, falling short of analyst expectations. The average amount customers spent per transaction increased by only 1.1% during the period. This marks a considerable deceleration from the 3.1% growth seen in the same quarter last year. Foot traffic remains steady, but shoppers are pulling back on their per-visit expenditures. Pharmacy Business Creates Headwinds A portion of the underperformance stemmed from Walmart’s pharmacy and health operations. Government-mandated prescription drug pricing negotiations created a 0.8% drag on comparable sales performance, according to company disclosures. The retailer announced plans to deploy $2.9 billion in tariff rebates toward maintaining competitive pricing. Additionally, Walmart projected an extra $2 billion in fuel-related expenses for the fiscal year. During the first quarter, Walmart had already absorbed a $175 million profitability hit from elevated energy expenses. The latest quarterly report intensified these worries. Paul Hickey, an analyst with Bespoke Investment Group, observed that the current report amplified negative sentiment that started emerging following the first-quarter results. Analyst Firms Reduce Valuation Targets Kate McShane, an analyst at Goldman Sachs, decreased her WMT price objective to $130 from the previous $141 while maintaining a Buy recommendation. McShane highlighted the improved second-half projections, double-digit profit margins in eCommerce operations, and opportunities for capturing additional market share as justification for continued optimism. Goldman’s earnings per share forecast for 2026 declined approximately 2%, roughly matching the stock’s percentage drop.